Napabucasin Attenuates Resistance of Breast Cancer Cells to Tamoxifen by Reducing Stem Cell-Like Properties

BACKGROUND: Tamoxifen (TAM) is the first-line drug for estrogen receptor-positive (ER+) breast cancer (BC) treatment. However, its resistance is a main obstacle in clinical practice. Thus, new therapeutic agents are urgently needed to fight TAM resistance. MATERIAL/METHODS: Here, we constructed TAM-...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Xueni, Huang, Jianhui, Xie, Yanru, Zhou, Yuefen, Wang, Renyi, Lou, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International Scientific Literature, Inc. 2019
Materias:
Lab/In Vitro Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886158/
https://www.ncbi.nlm.nih.gov/pubmed/31760402
http://dx.doi.org/10.12659/MSM.918384

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886158/
https://www.ncbi.nlm.nih.gov/pubmed/31760402
http://dx.doi.org/10.12659/MSM.918384

Ejemplares similares